1.11 Capital expenditure
In 2020, the tangible capital expenditure resulting from UCB biopharmaceutical activities amounted to € 256 million (2019: € 99 million) and are mainly related to the new campus site in the UK and the Bioplant in Belgium.
1.12 Statement of financial position
The intangible assets increased by € 2 134 million from € 839 million at December 31, 2019 to € 2 973 million at December 31, 2020.
1.13 Cash flow statement
The evolution of cash flow generated by bio-pharmaceuticals activities is affected by the following:
1.14 Outlook 2021
For 2021, UCB is aiming for revenues in the range of € 5.45 - 5.65 billion due to the current core product growth and new patient populations being served, despite of the ongoing pandemic.
2.1 Consolidated income statement
2.2 Consolidated statement of comprehensive income
2.3 Consolidated statement of financial position
2.4 Consolidated statement of cash flows
2.5 Consolidated statement of changes in equity
1. General information
UCB SA/NV (UCB or the Company) and its subsidiaries (together the Group) is a global biopharmaceutical company focused on severe diseases in two main therapeutic areas, namely Neurology and Immunology.